HLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.49%

Insider Buying (Last 12 Months): C$113,160.00

Insider Selling (Last 12 Months): C$0.00

HLS Therapeutics Insider Trading History Chart

HLS Therapeutics Share Price & Price History

C^$4.75

▲ +0.1 (2.15%)

As of 05/3/2024 01:00 AM ET

Days: 30 | 90 | 365

The asset beating inflation by 4x

From Colonial Metals | Ad

"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.

That's why we have released our Free Precious Metals Investment Guide that explains all the details

HLS Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/16/2023	Craig Millian	Director	Buy	5,000	C$2.60	C$13,000.00
11/15/2023	Brian Thomas Walsh	Senior Officer	Buy	1,000	C$2.91	C$2,910.00
11/10/2023	Polar Asset Management Partners Inc.	Insider	Buy	20,000	C$4.30	C$86,000.00
5/19/2023	Tim Hendrickson	Senior Officer	Buy	2,500	C$4.50	C$11,250.00
5/12/2022	William M. Wells	Director	Sell	50,000	C$12.51	C$625,710.00	838,575
12/13/2021	Tim Hendrickson	Senior Officer	Buy	400	C$14.63	C$5,852.00	42,900
8/27/2021	William M. Wells	Director	Sell	2,128	C$18.00	C$38,304.00	938,675
8/20/2021	Gilbert Godin	Director	Buy	2,000	C$17.50	C$35,000.00	20,000
6/16/2021	William M. Wells	Director	Sell	20,000	C$17.04	C$340,800.00	942,350

Elon to Transform U.S. Economy?

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

SEC Filings (Institutional Ownership Changes) for HLS Therapeutics (TSE:HLS)

59.62% of HLS Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Today's Range

Now: C$4.75

C$4.70

C$4.75

50 Day Range

MA: C$4.38

C$3.61

C$5.17

52 Week Range

Now: C$4.75

C$3.34

C$7.12

Volume

1,900 shs

Average Volume

9,112 shs

Market Capitalization

C$151.62 million

P/E Ratio

N/A

Dividend Yield

5.52%

Beta

1.16

Who are the company insiders with the largest holdings of HLS Therapeutics?: HLS Therapeutics' top insider investors include:
William M Wells (Director)
Brian Thomas Walsh (Senior Officer)
Craig Millian (Director)
Polar Asset Management Partners Inc (Insider)
Tim Hendrickson (Senior Officer)
Learn More about top insider investors at HLS Therapeutics.